Genetic Engineering of Probiotics as a Novel Therapeutic Strategy for the Management of Type 2 Diabetes Mellitus

Genetic Engineering of Probiotics as a Novel Therapeutic Strategy for the Management of Type 2 Diabetes Mellitus

Mahsima Aleemardani1 SarveAhrabi2

1) Department of Microbiology, SR.C., Islamic Azad University, Tehran, Iran.
2) Department of Biology, CT.C., Islamic Azad University, Tehran, Iran.

IOI Code : ABGZ-ABKEKD
Publication : The third international conference on new approaches in engineering and basic sciences(icnabs.ir)
Abstract :
    Type 2 diabetes mellitus (T2DM) has emerged as one of the most pressing global health challenges of the twenty-first century, with prevalence projections exceeding 780 million by 2045. Conventional pharmacotherapies, including insulin, metformin, and glucagon-like peptide-1 (GLP-1) receptor agonists, are constrained by short biological half-lives, parenteral administration requirements, suboptimal patient compliance, and substantial environmental costs associated with industrial synthesis. The gut microbiome has emerged as a critical regulator of glucose homeostasis, immune function, and metabolic health, providing a compelling rationale for microbiome-targeted therapeutic interventions. Recent advances in synthetic biology and genetic engineering have enabled the development of next-generation probiotics (NGPs) as programmable living therapeutics capable of in situ production of bioactive molecules, including GLP-1, insulin, and immunomodulatory peptides. This review synthesizes current evidence on engineered probiotic platforms for T2DM management, examining their molecular mechanisms of action, formulation strategies, preclinical efficacy, and translational barriers that must be addressed prior to clinical implementation.

Keywords : engineered probiotics type 2 diabetes mellitus glp 1 synthetic biology gut microbiome next generation probiotics